Cargando…
Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay
Screening for theranostic biomarkers is mandatory for the therapeutic management of cutaneous melanoma. BRAF and NRAS genes must be tested in routine clinical practice. The methods used to identify these alterations must be sensitive to detect mutant alleles in a background of wild type alleles, and...
Autores principales: | Vallée, Audrey, Denis-Musquer, Marie, Herbreteau, Guillaume, Théoleyre, Sandrine, Bossard, Céline, Denis, Marc G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6695223/ https://www.ncbi.nlm.nih.gov/pubmed/31415669 http://dx.doi.org/10.1371/journal.pone.0221123 |
Ejemplares similares
-
Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic BRAF or NRAS-Mutated Melanoma Patients
por: Herbreteau, Guillaume, et al.
Publicado: (2020) -
Efficient treatment of a metastatic melanoma patient with a combination of BRAF and MEK inhibitors based on circulating tumor DNA analysis: a case report
por: Quéreux, Gaelle, et al.
Publicado: (2017) -
NRAS(Q61R), BRAF(V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas
por: Uguen, Arnaud, et al.
Publicado: (2015) -
Atypical BRAF and NRAS Mutations in Mucosal Melanoma
por: Dumaz, Nicolas, et al.
Publicado: (2019) -
BRAF‐V600E immunohistochemistry in a large series of glial and glial–neuronal tumors
por: Breton, Quentin, et al.
Publicado: (2017)